H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Bausch Health Companies (NYSE:BHC) Inc on Monday, setting a price target of $64, which is approximately 250.30% above the present share price of $18.27.
Selvaraju expects Bausch Health Companies Inc to post earnings per share (EPS) of -$0.43 for the third quarter of 2020.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Bausch Health Companies, with an average price target of $27.86.
The analysts price targets range from a high of $64 to a low of $14.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $2.01 billion and a net profit of $301 million. The company's market cap is $6.48 billion.
According to TipRanks.com, H.C. Wainwright analyst Ram Selvaraju is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.4% and a 51.50% success rate.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.